Mitomycin Instillation to Prevent Recurrence of Superficial Bladder Carcinoma

Publisher Website
Google Scholar
Abstract
In a prospective randomized study, 58 patients with superficial bladder carcinoma received, after transurethral rejection (TUR), either no further therapy (30 patients) or mitomycin at 20 mg/20 ml instilled every 2 wk for the 1st yr and every 4 wk for the 2nd yr startng 3-4 wk afer TUR (28 patients). Bladder tumors recurred in only 2 patients in the treatment group; 15 patients in the control group had recurrences, with increases in grade in 4 patients and in stage in 6 patients. Three patients in the control group developed metastases, including one who died of his tumor; there were no tumor-related deaths in the mitomycin group.